Citations

Mayo Clinic

Showing 10 of 108599 citations.

Septic Arthritis in Emergency Departments in the US : A National Study of Health Care Utilization and Time Trends
Singh, Jasvinder A. , Yu, Shaohua , Singh, Jasvinder A

Arthritis Care & Research | May 2, 2017 | Volume: 70 | Issue: 2 | Pages: 320-326

10.1002/acr.23270 | PMID 28464432 Get It

Objective To assess the health care utilization and emergency department ( ED ) charges for septic arthritis. Methods We performed a retrospective cohort study of ED visits with septic arthritis as the primary diagnosis using the US Nationwide Emergency Department Sample data from 2009–2012. We examined ED charges, hospitalization, and associated time trends. Multivariable models were adjusted for demographics (age, sex, insurance status, residence, and household income), comorbidity, and hospital characteristics to assess factors associated with ED charges and hospitalization. Results Septic arthritis was responsible for 16,382 ED visits in 2012 in the US , which constituted 0.01% of all ED visits. The number of ED visits was stable from 2009–2012. Total ED charges were $34.6, $30.6, and $36.9 million in 2009, 2010, and 2012, respectively, and mean ED charges were $2,149, $1,866, and $2,257, respectively. The majority of the patients with an ED visit for septic arthritis were hospitalized: 82%, 83%, and 84% in 2009, 2010, and 2012, respectively. Metropolitan residence and western US location were associated with higher ED charges, and the highest income quartile, renal failure, or osteoarthritis were associated with lower ED charges. Female sex, metropolitan residence, metropolitan teaching hospital status, and medical comorbidity (diabetes mellitus, hyperlipidemia, hypertension, chronic obstructive pulmonary disease, coronary heart disease, gout, osteoarthritis, renal failure, and heart failure) were associated with a higher risk of hospitalization. Conclusion Comorbidities were associated with a higher risk of hospitalization after an ED visit for septic arthritis, but not higher ED charges. No time trends in ED visit incidence, ED charges, or hospitalization rate for septic arthritis from 2009–2012 were noted.
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27
Lipton, Allan, Chapman, Judith‐Anne W. , Leitzel, Kim, Garg, Ashwani, Budd, G. Thomas, Rabaglio, Manuela , Han, Lei , Elliott, Catherine, Shepherd, Lois E. , Goss, Paul E. , Ali, Suhail M., Ingle, James N. , Pritchard, Kathleen I. , Ellis, Matthew J. , Sledge, George W. , Rabaglio-Poretti, Manuela

Cancer | May 2, 2017 | Volume: 123 | Issue: 13 | Pages: 2444-2451

10.1002/cncr.30682 | PMID 28464211 Get It

BACKGROUNDBreast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of osteoporosis. This study examined the effects of self‐reported osteoporosis and osteoporosis therapy (OPT) on outcomes.METHODSThe MA.27 phase 3 adjuvant trial enrolled 7576 postmenopausal women. The primary outcome was event‐free survival (EFS), and the secondary outcome was distant disease–free survival (DDFS). Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis. In a multivariate, stratified Cox regression, factors were significant with a 2‐sided Wald test P value ≤ .05.RESULTSOsteoporosis was reported at the baseline by 654 of the 7576 women (8.6%) and in total by 1294 patients. Oral OPT was received at the baseline by 815 of the 7576 women (10.8%) and in total by 2711 patients (36%). With a median follow‐up of 4.1 years, 693 EFS events (9.15%) and 321 DDFS events (4.2%) occurred. Osteoporosis was not associated with EFS or DDFS. Few EFS events occurred before the initiation of OPT, with no substantive evidence of a time‐differing effect on outcomes (nonproportional hazards). OPT (yes vs no) was significantly associated with improved EFS (hazard ratio [HR] for yes vs no, 0.67; 95% confidence interval [CI], 0.57‐0.80; P < .001) and DDFS (HR, 0.57; 95% CI, 0.44‐0.73; P <. 001). Time‐differing (time‐dependent) OPT was not (EFS; P = .45). OPT did not alter the incidence of visceral‐only metastasis (P = .31).CONCLUSIONSOral OPT, administered to postmenopausal breast cancer patients receiving adjuvant AI therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time‐dependent effect) did not affect the outcome. OPT did not alter the risk of visceral metastasis. Cancer 2017;123:2444–51. © 2017 American Cancer Society.
Association between Alcohol Consumption, Folate Intake, and Risk of Pancreatic Cancer: A Case-Control Study
Yallew, Winta, Bamlet, William R. , Oberg, Ann L. , Anderson, Kristin E. , Olson, Janet E., Petersen, Gloria M. , Jansen, Rick J. , Olson, Janet E. , Sinha, Rashmi R. , Stolzenberg‐Solomon, Rachael Z. , Bamlet, William R , Jansen, Rick J

Nutrients | May 2, 2017 | Volume: 9 | Issue: 5 | Pages: 448

10.3390/nu9050448 | PMID 28468303 Get It

Pancreatic cancer is one of the most fatal common cancers affecting both men and women, representing about 3% of all new cancer cases in the United States. In this study, we aimed to investigate the association of pancreatic cancer risk with alcohol consumption as well as folate intake. We performed a case-control study of 384 patients diagnosed with pancreatic cancer from May 2004 to December 2009 and 983 primary care healthy controls in a largely white population (>96%). Our findings showed no significant association between risk of pancreatic cancer and either overall alcohol consumption or type of alcohol consumed (drinks/day). Our study showed dietary folate intake had a modest effect size, but was significantly inversely associated with pancreatic cancer (odds ratio (OR) = 0.99, p < 0.0001). The current study supports the hypothesis that pancreatic cancer risk is reduced with higher food-based folate intake.
Potential role of high-stress employment in hypertension
Buenz, Eric J. , Bauer, Brent A.

JRSM Open | May 2, 2017 | Volume: 8 | Issue: 5 | Pages: No page available

10.1177/2054270417694292 | PMID 28515952 Get It

We report a patient with a reduction in blood pressure through cessation of high-stress employment.
Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials
Howard, Virginia J. , Lal, Brajesh K. , Turan, Tanya N. , Roubin, Gary S., Brown, Robert D. , Voeks, Jenifer H. , Barrett, Kevin M. , Lazar, Ronald M. , Moore, Wesley S. , Wadley, Virginia G. , Moy, Claudia S., Chimowitz, Marc I. , Howard, George , Brott, Thomas G. , Meschia, James F. , Demaerschalk, Bart M. , Huston, John , Chaturvedi, Seemant , Howard, Virginia J , Howard, George

International Journal of Stroke | May 2, 2017 | Volume: 12 | Issue: 7 | Pages: 770-778

10.1177/1747493017706238 | PMID 28462683 Get It

Rationale Trials conducted decades ago demonstrated that carotid endarterectomy by skilled surgeons reduced stroke risk in asymptomatic patients. Developments in carotid stenting and improvements in medical prevention of stroke caused by atherothrombotic disease challenge understanding of the benefits of revascularization. Aim Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) will test whether carotid endarterectomy or carotid stenting plus contemporary intensive medical therapy is superior to intensive medical therapy alone in the primary prevention of stroke in patients with high-grade asymptomatic carotid stenosis. Methods and design CREST-2 is two multicenter randomized trials of revascularization plus intensive medical therapy versus intensive medical therapy alone. One trial randomizes patients to carotid endarterectomy plus intensive medical therapy versus intensive medical therapy alone; the other, to carotid stenting plus intensive medical therapy versus intensive medical therapy alone. The risk factor targets of centrally directed intensive medical therapy are LDL cholesterol <70 mg/dl and systolic blood pressure <140 mmHg. Study outcomes The primary outcome is the composite of stroke and death within 44 days following randomization and stroke ipsilateral to the target vessel thereafter, up to four years. Change in cognition and differences in major and minor stroke are secondary outcomes. Sample size Enrollment of 1240 patients in each trial provides 85% power to detect a treatment difference if the event rate in the intensive medical therapy alone arm is 4.8% higher or 2.8% lower than an anticipated 3.6% rate in the revascularization arm. Discussion Management of asymptomatic carotid stenosis requires contemporary randomized trials to address whether carotid endarterectomy or carotid stenting plus intensive medical therapy is superior in preventing stroke beyond intensive medical therapy alone. Whether carotid endarterectomy or carotid stenting has favorable effects on cognition will also be tested. Trial registration United States National Institutes of Health Clinicaltrials.gov NCT02089217
Medicaid Savings From The New York University Caregiver Intervention for Families with Dementia
Moriarty, James P. , Farseth, Paul, Mittelman, Mary , Long, Kirsten Hall , Foldes, Steven S.

The Gerontologist | May 2, 2017 | Volume: 58 | Issue: 2 | Pages: e97-e106

10.1093/geront/gnx077 | PMID 29106531 Get It

Polymyalgia Rheumatica
Matteson, Eric L. , Dejaco, Christian , Dejaco, Christian

Annals of Internal Medicine | May 1, 2017 | Volume: 166 | Issue: 9 | Pages: ITC65-ITC80

10.7326/aitc201705020 | PMID 28460395 Get It

Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor
Hinson, Shannon R., Clift, Ian C. , Luo, Ningling, Kryzer, Thomas J., Lennon, Vanda A.

Proceedings of the National Academy of Sciences | May 1, 2017 | Volume: 114 | Issue: 21 | Pages: 5491-5496

10.1073/pnas.1701960114 | PMID 28461494 Get It

Significance Neuromyelitis optica (NMO) is a severe inflammatory central nervous system demyelinating disease (IDD). Detection of NMO-specific IgG in serum distinguishes NMO from other IDDs, enables rapid diagnosis, and expedites NMO-appropriate therapy. Binding of NMO-IgG to aquaporin-4 (AQP4), the astrocytic water channel antigen, initiates endocytosis of AQP4 and its coupled EAAT2 glutamate transporter. Sequelae potentially contributing to NMO lesions include reduced water fluxes, reduced extracellular glutamate clearance, activation of a proinflammatory astrocyte response, and complement activation. Our paper investigates early events following IgG–AQP4 interaction and demonstrates that AQP4 and EAAT2 internalization, but not astrocytic secretion of IL-6, requires astrocytic Fc receptor signaling. Selective attenuation of these signaling events offers an upstream therapeutic target.
Response by Fender et al to Letter Regarding Article, “Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes”
Fender, Erin A. , Holmes, David R. , Packer, Douglas L. , Widmer, R. Jay

Circulation | May 1, 2017 | Volume: 135 | Issue: 18 | Pages: No page available

10.1161/circulationaha.117.027480 | PMID 28461424 Get It

Aortic Valve Bioprostheses
Holmes, David R. , Mack, Michael J.

Circulation | May 1, 2017 | Volume: 135 | Issue: 18 | Pages: 1749-1756

10.1161/circulationaha.116.025429 | PMID 28461416 Get It

Leaflet immobility and valve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses. The relationships between these abnormalities and their incidence, time course, clinical significance, predisposing factors, optimal imaging modality, and current therapeutic options remain uncertain but are rapidly evolving. Four-dimensional computerized tomographic imaging has been determined to have the highest sensitivity in studies evaluating leaflet immobility and valve thrombosis. Echocardiography is also used during surveillance, but it appears to be less sensitive. The definitive diagnosis of valve thrombosis is based on a combination of diagnostic 4-dimensional computerized tomographic imaging findings, resolution of imaging abnormalities, and elevated transcatheter gradients with anticoagulation or surgical or pathological confirmation. Uncertainty about the incidence and clinical significance of the findings is the basis of 2 US Food and Drug Administration–approved studies comparing transcatheter and surgical aortic valve replacement with a subset undergoing surveillance 4-dimensional computerized tomographic imaging. Given the expansion of transcatheter aortic valve procedures, including potentially lower-risk patients, the resolution of these uncertainties is critical.